Top

Strahlentherapie und Onkologie

Published in:

13-06-2022 | Kidney Cancer | Original Article

Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

Authors: Cem Onal, Ozan Cem Guler, Pervin Hurmuz, Guler Yavas, Burak Tilki, Ezgi Oymak, Cagdas Yavas, Gokhan Ozyigit

Published in: Strahlentherapie und Onkologie | Issue 10/2022

Abstract

Purpose

This study aimed to analyze the prognostic factors associated with overall survival (OS) and progression-free survival (PFS) in patients with bone-only metastatic renal cell carcinoma (RCC) who have five or fewer lesions treated with stereotactic body radiotherapy (SBRT).

Methods

The clinical data of 54 patients with 70 bone metastases undergoing SBRT treated between 2013 and 2020 with a dose of at least 5 Gy per fraction and a biologically effective dose (BED) of at least 90 Gy were retrospectively evaluated.

Results

The majority of lesions were located in the spine (57.4%) and had only one metastasis (64.8%). After a median follow-up of 22.4 months, the 1‑ and 2‑year OS rates were 84.6% and 67.3%, respectively, and median OS was 43.1 months. The 1‑ and 2‑year PFS rates and median PFS were 63.0%, 38.9%, and 15.3 months, respectively. In SBRT-treated lesions, the 1‑year local control (LC) rate was 94.9%. Age, metastasis localization, and number of fractions of SBRT were significant prognostic factors for OS in univariate analysis. In multivariate analysis, patients with spinal metastasis had better OS compared to their counterparts, and patients who received single-fraction SBRT had better PFS than those who did not. No patient experienced acute or late toxicities of grade 3 or greater.

Conclusion

Despite excellent LC at the oligometastatic site treated with SBRT, disease progression was observed in nearly half of patients 13 months after metastasis-directed local therapy, particularly as distant disease progression other than the treated lesion, necessitating an effective systemic treatment to improve treatment outcomes.

Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38:284–291. https://doi.org/10.1016/j.ctrv.2011.06.011CrossRefPubMed

Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160–166. https://doi.org/10.1016/j.bone.2010.09.008CrossRefPubMed

Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23(4):973–980. https://doi.org/10.1093/annonc/mdr362CrossRefPubMed

Santini D, Procopio G, Porta C et al (2013) Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. Plos One 8(12):e83026. https://doi.org/10.1371/journal.pone.0083026CrossRefPubMedPubMedCentral

Santoni M, Conti A, Procopio G et al (2015) Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res 34:10. https://doi.org/10.1186/s13046-015-0122-0CrossRefPubMedPubMedCentral

Kalra S, Verma J, Atkinson BJ et al (2017) Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer 15(3):363–370. https://doi.org/10.1016/j.clgc.2017.01.010CrossRefPubMed

McKay RR, Kroeger N, Xie W et al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 65(3):577–584. https://doi.org/10.1016/j.eururo.2013.08.012CrossRefPubMed

Dabestani S, Marconi L, Hofmann F et al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol 15(12):e549–e561. https://doi.org/10.1016/S1470-2045(14)70235-9CrossRefPubMed

10.

Grunwald V, Eberhardt B, al Bex A (2018) An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nat Rev Urol 15(8):511–521. https://doi.org/10.1038/s41585-018-0034-9CrossRefPubMedPubMedCentral

11.

Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8CrossRefPubMed

12.

Meyer E, Pasquier D, Bernadou G et al (2018) Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: a study of the GETUG group. Eur J Cancer 98:38–47. https://doi.org/10.1016/j.ejca.2018.04.008CrossRefPubMed

13.

Wang CJ, Christie A, Lin MH et al (2017) Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys 98(1):91–100. https://doi.org/10.1016/j.ijrobp.2017.01.032CrossRefPubMedPubMedCentral

14.

Marvaso G, Corrao G, Oneta O et al (2021) Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol 23(8):1717–1726. https://doi.org/10.1007/s12094-021-02574-0CrossRefPubMed

15.

Franzese C, Marvaso G, Francolini G et al (2021) The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group. Clin Exp Metastasis 38(6):527–537. https://doi.org/10.1007/s10585-021-10131-wCrossRefPubMed

16.

Ning S, Trisler K, Wessels BW, Knox SJ (1997) Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer 80(12 Suppl):2519–2528PubMed

17.

Guerrero M, Li XA (2004) Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49(20):4825–4835. https://doi.org/10.1088/0031-9155/49/20/012CrossRefPubMed

18.

Song CW, Lee YJ, Griffin RJ et al (2015) Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93(1):166–172. https://doi.org/10.1016/j.ijrobp.2015.05.016CrossRefPubMedPubMedCentral

19.

Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88(2):254–262. https://doi.org/10.1016/j.ijrobp.2013.07.022CrossRefPubMedPubMedCentral

20.

Park HJ, Griffin RJ, Hui S et al (2012) Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res 177(3):311–327. https://doi.org/10.1667/rr2773.1CrossRefPubMed

21.

Kothari G, Foroudi F, Gill S et al (2015) Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol 54(2):148–157. https://doi.org/10.3109/0284186X.2014.939298CrossRefPubMed

22.

Ruhle A, Andratschke N, Siva S, Guckenberger M (2019) Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 18:104–112. https://doi.org/10.1016/j.ctro.2019.04.012CrossRefPubMedPubMedCentral

23.

Altoos B, Amini A, Yacoub M et al (2015) Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol 10:218. https://doi.org/10.1186/s13014-015-0528-zCrossRefPubMedPubMedCentral

24.

Beuselinck B, Oudard S, Rixe O et al (2011) Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 22(4):794–800. https://doi.org/10.1093/annonc/mdq554CrossRefPubMed

25.

Zaorsky NG, Lehrer EJ, Kothari G et al (2019) Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): A meta-analysis of 28 studies. Eur Urol Oncol 2(5):515–523. https://doi.org/10.1016/j.euo.2019.05.007CrossRefPubMed

26.

Zelefsky MJ, Greco C, Motzer R et al (2012) Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82(5):1744–1748. https://doi.org/10.1016/j.ijrobp.2011.02.040CrossRefPubMed

27.

De B, Venkatesan AM, Msaouel P et al (2021) Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. https://doi.org/10.1111/bju.15541CrossRefPubMed

28.

Zhang Y, Schoenhals J, Christie A et al (2019) Stereotactic ablative radiation therapy (SAbR) used to defer systemic therapy in oligometastatic renal cell cancer. Int J Radiat Oncol Biol Phys 105(2):367–375. https://doi.org/10.1016/j.ijrobp.2019.07.023CrossRefPubMedPubMedCentral

29.

Ranck MC, Golden DW, Corbin KS et al (2013) Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 36(6):589–595. https://doi.org/10.1097/COC.0b013e31825d52b2CrossRefPubMed

30.

Cheung P, Patel S, North SA et al (2021) Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: A phase 2 prospective multicenter study. Eur Urol 80(6):693–700. https://doi.org/10.1016/j.eururo.2021.07.026CrossRefPubMed

31.

Spencer KL, van der Velden JM, Wong E et al (2019) Systematic review of the role of stereotactic radiotherapy for bone metastases. J Natl Cancer Inst 111(10):1023–1032. https://doi.org/10.1093/jnci/djz101CrossRefPubMedPubMedCentral

32.

Sahgal A, Larson DA, Chang EL (2008) Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 71(3):652–665. https://doi.org/10.1016/j.ijrobp.2008.02.060CrossRefPubMed

Title: Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study
Authors: Cem Onal
Ozan Cem Guler
Pervin Hurmuz
Guler Yavas
Burak Tilki
Ezgi Oymak
Cagdas Yavas
Gokhan Ozyigit
Publication date: 13-06-2022
Publisher: Springer Berlin Heidelberg
Keywords: Kidney Cancer
Metastasis
Kidney Cancer
Kidney Cancer
Radiotherapy
Bone Metastasis
Spinal Metastasis
Published in: Strahlentherapie und Onkologie / Issue 10/2022
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-01962-x

At a glance: The STEP trials

Springer Medicine

Bone-only oligometastatic renal cell carcinoma patients treated with stereotactic body radiotherapy: a multi-institutional study

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2022

Evaluation of the ability of the Brainlab Elements Cranial Distortion Correction algorithm to correct clinically relevant MRI distortions for cranial SRT

Risikostandardisierte Mortalitätsraten übertreffen als Qualitätsindikator die typischen „Mindestzahlen“ in der onkologischen Chirurgie – ein neuer Blick auf Krankenhauszentralisationen mithilfe nationaler bevölkerungsbezogener Daten

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy

Correction to: Comparison of 3D and 4D Monte Carlo optimization in robotic tracking stereotactic body radiotherapy of lung cancer

Stereotactic radiotherapy of brain metastases: clinical impact of three-dimensional SPACE imaging for 3T-MRI-based treatment planning

Antiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and heck squamous cell carcinoma: a prospective phase II trial